- Durata Therapeutics
-
Durata Therapeutics, established in 2009, is a clinical development stage pharmaceutical company. Durata focuses on new therapeutics to treat infectious diseases.
Durata has several projects in its pipeline, most notably the antibacterial, dalbavancin. The company acquired this long-acting semisynthetic lipoglycopeptide antibiotic from Pfizer in December 2009.[1] Durata has since initiated two Phase III studies of dalbavancin for intravenous (IV) treatment of acute bacterial skin and skin structure infections.[2]
References
- ^ Durata Therapeutics Acquires Pfizer’s Subsidiary that Develops Antibiotics. GEN News Highlights: Dec 21, 2009.
- ^ Durata Begins Dalbavancin Study Enrollment. Drug Discovery & Development - October 05, 2011.
External links
Durata Therapeutics corporate website
Categories:- Company stubs
- Pharmaceutical companies of the United States
Wikimedia Foundation. 2010.